<DOC>
	<DOCNO>NCT02912377</DOCNO>
	<brief_summary>Multiple-doses , randomise , double-blind , three-periods , two-sequences crossover study assess immunogenicity pharmacodynamic comparability biosimilar pegfilgrastim ( B12019 ) reference product Neulasta® healthy subject</brief_summary>
	<brief_title>Immunogenicity Pharmacodynamic B12019 Neulasta® Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male subject , 18 55 year age ( inclusive ) . 2 . BMI 20.0 30.0 kg/m² ( inclusive ) . 3 . Weight 60 100 kg ( inclusive ) . 4 . Nonsmoker least 3 month mild smoker consumption le 5 cigarette ( equivalent ) per day prior study start . 5 . Healthy subject determine medical history , physical examination include vital sign , ECG clinical laboratory test . 6 . Able comply protocol requirement , include overnight stay , blood sample collection define protocol participate entire trial period . 7 . Subjects able willing give write informed consent . 8 . Male subject female spouse/partner childbearing potential must use effective contraception start screen continue throughout clinical study period . 9 . Male subject must donate sperm start screen throughout clinical study period 3 month final study drug administration . History : 1 . Evidence subject 's medical history medical examination clinically significant hepatic , renal , gastrointestinal , cardiovascular , pulmonary , haematological , central nervous system diseases significant acute chronic disease , especially hereditary fructose intolerance , might influence either safety subject absorption , metabolism excretion active agent investigation . 2 . Subjects clinically relevant neurologic psychiatric illness . 3 . Subjects clinically relevant allergy ( except untreated , asymptomatic , seasonal allergy time dose ) . 4 . Previous exposure pegfilgrastim . 5 . Known hypersensitivity Escherichia coliderived protein , pegfilgrastim , filgrastim component B12019 Neulasta® list section 7.2 . 6 . History allergy recombinant protein . 7 . History cancer . 8 . History haematological disease , include sickle cell disorder . 9 . History pulmonary infiltrates pneumonia within 6 month first study drug administration . 10 . Known antidrug antibody filgrastim pegfilgrastim , include know antibody PEG consequence exposure PEG pegfilgrastim ( e.g . cosmetic , etc. ) . 11 . Subjects willing able comply food beverage restriction ( grapefruit/pomelo , starfruit , poppy seed ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>